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Abstract 
 
Motor neuron diseases (MNDs) are neurodegenerative diseases that involve loss 
of motor neurons in the brain and spinal cord.  MNDs are debilitating and often fatal. 
Distal hereditary motor neuropathies (dHMNs) are a category of MND characterized by 
progressive, distal weakness without loss of sensation. The primary focus of our 
laboratory is to understand the functional consequences of mutations in small heat shock 
proteins (sHSPs) that result in dHMN. sHSPs comprise a family of 10 homologous 
proteins that are characterized by a central alpha-crystallin domain, are expressed 
ubiquitously, serve neuroprotective functions, and are upregulated by cell stress. To date, 
mutations in three sHSPs: HSPB1, HSPB3 and HSPB8, have been associated with 
dHMN. These mutations include HSPB1(R136W) and HSPB3(R7S).  We propose that 
mutations reported in these proteins affect the same cellular pathway because they all 
lead to the same clinical phenotype and loss of motor neurons.  
HSPB1 is the best characterized sHSP and is required for AU-rich element 
(ARE)-dependent mRNA decay. AREs are adenosine and uridine rich regions that are 
present in the 3’ untranslated region of a subset of mRNAs that signal for their rapid 
decay. We hypothesize that dHMN-associated mutations result in dysregulation of this 
critical mRNA decay pathway, and that mutations in HSPB1 and in HSPB3 result in an 
increased half-life of ARE-containing mRNAs. To determine the effect of sHSP 
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mutations on ARE-mediated mRNA decay, we measured the rate of ARE-mediated 
mRNA decay in macrophages transfected with the wild-type HSPB1 gene or the mutant 
HSPB1(R136W) gene.  However, these experiments must be replicated before 
conclusions can be drawn about the role of HSPB1(R136W) in ARE-mediated mRNA 
decay in vitro.  To determine the effect of the HSPB1(R136W) on ARE-mediated mRNA 
decay  in vivo, we developed transgenic mice expressing either the wild-type HSPB1 or 
mutant HSPB1(R136W) trangenes under the prion-protein promoter (PrP) to ensure high 
expression of the wild-type HSPB1 and mutant HSPB1(R136W) transgenes in neurons.  
We determined that expression of the PrP-driven HSPB1(R136W) transgene resulted in a 
subclinical motor neuropathy.  We will use this mouse model in the future to determine 
the effect of mutant HSPB1(R136W) on ARE-mediated mRNA decay in vivo. 
Little is known about the function of wild-type HSPB3 or about the effect of 
HSPB3(R7S) on that function.  Therefore, we have begun to characterize wild-type and 
mutant HSPB3.  Further studies must be performed to determine the effect of HSPB3 and 
HSPB3(R7S) on ARE-mediated mRNA decay in vitro and in vivo.  Determining the 
effect of these small heat shock protein mutations on ARE-mediated mRNA decay in 
vitro and in vivo will further our mechanistic understanding of how small heat shock 
protein mutations lead to dHMN, and MNDs in general.   
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Chapter 1 
 
Problem Statement 
Motor Neuron Diseases 
 Motor neuron diseases (MNDs) are neurodegenerative diseases characterized by 
motor neuron loss and progressive muscle weakness in the limbs.  MNDs are debilitating, 
lead to poor quality of life, and are often fatal.  Some examples of MNDs are 
amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, the spinal 
muscular atrophies (SMAs), and the distal hereditary motor neuropathies (dHMNs).  ALS 
is always fatal, but SMAs and dHMN are not necessarily fatal.  In particular, about 6 in 
100,000 people are diagnosed with ALS [1] and this disease is usually fatal within 5 
years of the diagnosis [2].  Unfortunately, there are no effective treatments for MNDs.  
One of the interesting questions in MND research has to do with motor neuron 
selectivity: how do mutations in genes that are expressed in all cells result in a motor 
neuron selective disease? 
 To answer this question, the mechanism of MNDs must be determined.  Because 
MNDs are related and have similar clinical phenotypes, MNDs may develop via a 
common mechanism that affects a common pathway.  One of these proposed common 
pathways is altered RNA processing [3].  Altered ARE-mediated mRNA decay is 
hypothesized to contribute to the mechanism of dHMN (preliminary evidence).  
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Therefore, we studied ARE-mediated mRNA decay in different MND model systems to 
determine if altered ARE-mediated mRNA decay should be considered a possibility for a 
common affected pathway in MNDs.  We hypothesize that ARE-mediated mRNA decay 
is altered in dHMN as well as other MNDs, including ALS. 
 
Literature Review 
Distal Hereditary Motor Neuropathy 
Our laboratory primarily focuses on distal hereditary motor neuropathy (dHMN).  
dHMN is a debilitating MND characterized by progressive weakness in the toes and feet 
without loss of sensation [4].  In humans, there are axonal dHMNs and demylinating 
dHMNs.  Certain mutations in small heat shock proteins have been associated with 
axonal dHMN [5-9].     
 
Small Heat Shock Proteins  
 Small heat shock proteins (sHSPs) are a family of 10 homologous proteins 
characterized by a central alpha-crystallin domain responsible for the formation of sHSP 
complexes.[10,11].  sHSPs are expressed in all cells, and their expression is induced by a 
variety of cell stressors such as heat, ultraviolet light, and cardiac ischemia.[12,13].  
Multiple functions have been ascribed to these proteins.  Functions characterized thus far 
include the prevention of apoptosis, rearrangements of the cytoskeleton, their roles as 
molecular chaperones, and actin polymerization [10, 14].   
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Interestingly, mutations in 3 of these 10 proteins, HSPB1, HSPB3, and HSPB8, 
result in dHMN [5-7, 9] (Figure 1).  These mutations include HSPB1(R136W) and 
HSPB3(R7S) [7, 9].  The overall goal of my research is to characterize the functional 
consequences of these mutations.  The dHMN-associated sHSP mutations are not specific 
to any one sHSP domain (Figure 1).  sHSP mutations associated with dHMN are found in 
the alpha-crystallin domain, the C-terminal domain, and the N-terminal domain. If all of 
these mutations occurred in the alpha-crystallin domain, then sHSP binding and complex 
formation would most likely contribute to the mechanism of these mutations leading to 
dHMN.  However, only 2/3 of these sHSP disease-causing mutations occur in the alpha-
crystallin domain.  Therefore, there is most likely some other essential function of sHSPs 
that must be altered for dHMN to develop.     
 
 
  
 
 
 
 
 
 
Of the ten sHSPs, HSPB1 has been the most extensively studied.   As discussed 
above, mutant HSPB1(R136W) causes dHMN [7].  However, wild-type HSPB1 is 
Figure 1. Mutations in sHSPs associated with dHMN.   
Mutations in HSPB1, HSPB3, and HSPB8 that are associated with dHMN are indicated by the red 
diamonds.  The green region denotes the alpha-crystallin domain. 
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actually neuroprotective in neurons, meaning that it promotes neuron survival [15].  Just 
as the mechanism of sHSP mutations causing dHMN is unknown, the mechanism by 
which wild-type HSPB1 is neuroprotective is also not known.  
 
ARE-mediated mRNA decay 
One important way that gene expression is controlled is by the regulation of 
mRNA decay.  There are many different pathways involved in the decay of mRNAs.  
One of these pathways is ARE-mediated mRNA decay.  AREs are adenosine and uridine 
rich regions in the 3’ untranslated region of a subset of mRNAs [14].  It is known that 
when a protein complex called AUF1-and signal transduction regulated complex binds to 
an ARE, the complex attracts mRNA degradation machinery and initiates mRNA decay 
[14].  HSPB1 is part of this AUF1 protein complex that binds to the ARE and thus helps 
to initiate ARE-mediated mRNA decay (Figure 2) [14].  HSPB1 can only initiate mRNA 
decay if there is an ARE on an mRNA; otherwise, the AUF1 complex containing HSPB1 
cannot bind to the mRNA, and the mRNA must be degraded via another mechanism, or it 
will not be degraded at all.   
 
 
 
 
 
 
5 
 
 
 
 
 
 
 
 
 
 
 
We have hypothesized that ARE-mediated mRNA decay is altered in dHMN 
patients with HSPB1 mutations.  To test this hypothesis, we developed a luciferase 
reporter assay. We transfected stable HeLa cells over-expressing wild-type or mutant 
HSPB1 with a wild-type or mutant luciferase reporter (Figure 3).  The wild-type 
luciferase reporter did not have an ARE on its mRNA.  The mutant luciferase reporter 
had the ARE region from TNFα on its mRNA.  In the presence of wild-type HSPB1, the 
steady state level of the ARE luciferase reporter was decreased compared to the wild-type 
luciferase reporter.  However, in the presence of HSPB1(R136W), the steady state level 
of the ARE luciferase reporter was the same as the steady state level of the wild-type 
luciferase reporter.  This assay did not directly measure the rate of ARE-mediated mRNA 
decay; therefore, the observed increase in steady state levels of the ARE luciferase 
reporter in the presence of HSPB1(R136W) compared to in the presence of wild-type 
A. 
B. 
Figure 2. HSPB1 initiates ARE-mediated mRNA decay. 
A. HSPB1 initiates ARE-mediated mRNA decay by binding to the ARE as part of the AUF1 complex.  
Normal levels of the transcribed protein are expressed. 
B. HSPB1 does not initiate mRNA decay without an ARE.  The transcribed protein is over-expressed. 
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HSPB1 could be a result of altered ARE-mediated mRNA decay of the ARE reporter, or 
a result of an increase in production of the ARE luciferase reporter in the presence of 
HSPB1(R136W).  Currently, we are using assays that measure mRNA decay directly to 
clarify whether or not HSPB1(R136W) actually alters ARE-mediated mRNA decay.   
 
 
 
 
 
  
 
 
 
 
 
 
Current Study 
We propose that all mutations reported in HSPB1, HSPB3, and HSPB8 affect the 
same cellular pathway because they all lead to the same clinical phenotype. It may be that 
these mutations act by a common mechanism to cause dHMN, even if they have different 
immediate effects in the cells.  To determine how mutations in these different sHSPs lead 
to dHMN, we studied whether RNA processing is the relevant defect in dHMN.  Since it 
Figure 3. Preliminary evidence that HSPB1(R136W) inhibits ARE-mediated mRNA decay. 
A. Constructs of the luciferase reporter genes.  The wild-type luciferase reporter does not contain an 
ARE on its mRNA.  The mutant luciferase reporter contains the TNFα ARE on its mRNA.  B. After 
24 hours of transfection with the luciferase reporters, RNA was isolated from HeLa cells, and 
converted to cDNA via reverse transcription PCR.  The graph shows the QPCR of the cDNA.  
(Courtesy Dr. Shuping Gu.) 
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is clear that wild-type HSPB1 plays a role in ARE-mediated mRNA decay [12-14] and 
we have preliminary evidence that mutant HSPB1(R136W) alters ARE-mediated mRNA 
decay, we also looked at the function of wild-type and mutant HSPB3 in ARE-mediated 
mRNA decay.  We hypothesized that the mutations in HSPB1 and HSPB3 affect ARE-
mediated mRNA decay leading to a decrease in mRNA degradation, an increase in 
mRNA translation and protein expression, and ultimately the development of dHMN. 
Because mutations in genes associated with MNDs such as ALS, SMA, and lethal 
congenital contracture syndrome (LCCS) are involved in RNA processing, we studied 
RNA processing in a model of ALS in addition to models of dHMN [3].  Determining the 
effect of sHSP mutations on mRNA decay and the effect of an ALS model on mRNA 
decay will further help us to determine the mechanism of MNDs.   
 
Hypothesis 
We hypothesized that the HSPB1(R136W) and HSPB3(R7S) mutations will alter 
the activity and function of HSPB1 and HSPB3, respectively.  Specifically, we 
hypothesized that HSPB1(R136W) and HSPB3(R7S) will affect the function of HSPB1 
(and possibly HSPB3) in ARE-mediated mRNA decay, ultimately leading to dHMN.  In 
addition, we hypothesized that ARE-mediated mRNA decay is altered in vivo. 
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Specific Aims 
Mutations in HSPB1 and HSPB3 result in dHMN [7, 9].  It is known that HSPB1 
is required for ARE-mediated mRNA decay [14].  To determine the relevant functional 
consequences of these mutations, I proposed the following specific aims: 
Aim 1. To determine the effect of HSPB1 mutations on ARE-mediated mRNA 
decay.  I measured the rate of mRNA decay of ARE-containing mRNAs and compared 
the rates of mRNA decay in the presence of wild-type or mutant HSPB1.   
Aim 2. To determine whether ARE-mediated mRNA decay is altered in vivo.  I 
helped develop a murine model of dHMN which will be used in future in vivo studies of 
ARE-mediated mRNA decay.  
Aim 3. To determine whether ARE-mediated mRNA decay is altered by the 
expression of HSPB3.  I will measure the decay rate of an ARE-containing mRNA in the 
presence of wild-type or mutant HSPB3.   
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Aim 1. To determine the effect of HSPB1 mutations on ARE-mediated mRNA decay. 
 Mutations in HSPB1 are known to cause dHMN [7].  It is known that HSPB1 is 
involved in ARE-mediated mRNA decay [14].  We have preliminary results showing that 
the disease-causing mutation, HSPB1(R136W), leads to overexpression of proteins, 
indicating that HSPB1(R136W) may inhibit ARE-mediated mRNA decay (unpublished 
data) (Figure 3).  However, these preliminary experiments measured mRNA decay 
indirectly.  Therefore, here, to determine the effect of HSPB1(R136W) on mRNA decay, 
we measured mRNA decay directly.  We used QPCR to measure the levels of TNFα 
mRNA, an ARE-containing mRNA, from mouse macrophages that endogenously express 
TNFα.  We measured the levels of TNFα mRNA at different time points, and thus were 
able to directly measure the rate of ARE-mediated mRNA decay.  We hypothesized that 
HSPB1(R136W) inhibits ARE-mediated mRNA decay, and that this inhibition 
contributes to the mechanism of dHMN.  Determining the effect of mutant HSPB1 on 
ARE-mediated mRNA decay will help us determine whether altered ARE-mediated 
mRNA decay is part of the mechanism of HSPB1 mutations leading to dHMN. 
 
Aim 2: To determine whether ARE-mediated mRNA decay is altered in vivo. 
 Performing the ARE-mRNA decay assay on mouse macrophages helps to 
determine the role of sHSP mutations on mRNA decay in vitro.  However, we also aim to 
determine the effect of sHSP mutations on mRNA decay in vivo.  To determine the 
function of the HSPB1(R136W) mutation on mRNA decay in vivo, I have spent much of 
my early work in the lab developing a novel mouse model of the HSPB1(R136W) 
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mutation.   These mice exhibited no difference in longevity, motor activity, or behavior 
compared to wild-type HSPB1 transgenic and non-transgenic control mice.  However, 
they did show electrophysiological and pathological evidence of a subclinical axonal 
neuropathy.  In the future, we will use these transgenic mice to determine the effect of the 
HSPB1(R136W) mutation on ARE-mediated mRNA decay in vivo by directly measuring 
the rate of mRNA decay from tissue samples from these animals.  Determining whether 
HSPB1(R136W) leads to altered ARE-mediated mRNA decay in vivo will give us further 
evidence as to whether or not ARE-mediated mRNA decay contributes to the mechanism 
of dHMN caused by mutations in HSPB1. 
 
Aim 3: To determine whether ARE-mediated mRNA decay is altered by the expression of 
HSPB3 
Since HSPB3 is homologous to HSPB1 and HSPB8, we believe that the 
HSPB3(R7S) mutation leads to the same functional consequences, and thus acts by the 
same mechanism as the mutations in HSPB1 and HSPB8 to cause dHMN.  However, 
little is known about the function of HSPB3.  Therefore, we have begun to characterize 
wild-type and mutant HSPB3.  We have determined the subcellular localization of wild-
type HSPB3 and mutant HSPB3(R7S).  In the future, we plan to determine whether 
HSPB3 functions in ARE-mediated mRNA decay and how HSPB3(R7S) alters that 
function.  We will perform the same assays as in Aim 1, but with HSPB3 and 
HSPB3(R7S) instead of wild-type and mutant HSPB1.  We hypothesize that wild-type 
HSPB3 will lead to ARE-mediated mRNA decay compared to untransfected cells, and 
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HSPB3(R7S) will lead to a deficiency in ARE-mediated mRNA decay compared to cells 
overexpressing wild-type HSPB3.  Determining the effect of mutant and wild-type 
HSPB3 will help us to determine whether ARE-mediated mRNA decay is likely part of 
the common pathway of sHSP mutations causing dHMN. 
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Chapter 2 
  
Materials and Methods 
Harvesting Macrophages 
Bone marrow derived macrophages were harvested from a mouse according to the 
Popovich lab protocol (Courtesy Dr. Phillip Popovich).  A mouse was anesthetized with 
approximately 0.7 ml ketamine HCL/xylazine HCl solution (Sigma) and then euthanized 
by cervical dislocation.  Alternatively, some mice were euthanized by CO2 and then 
cervical dislocation. Then, the femur and tibia were flushed with DMEM/F12 + 
Glutamax media (Gibco) or PBS (Gibco).  The media/cell solution was centrifuged at 
1200 rpm for 5 minutes.  The red blood cells were then lysed and removed from the bone 
marrow cells.  The bone marrow cells were plated onto 10 cm dishes (Corning) in 
Advanced DMEM/F12 reduced serum (Gibco) with recombinant mouse granulocyte 
macrophage colony stimulating factor (0.1µg/ml), 5% L-glutamine (Cellgro), 10% FBS 
(Gibco), and 1% penicillin/streptomycin (Cellgro) and cultured at 37°C for at least 7 
days. 
 
Macrophage Stimulation 
Macrophages were seeded into 6 well plates and left overnight.  Macrophages 
were stimulated with lipopolysaccharide (LPS) (1 µg/ml) for 2 hours.  Then, transcription 
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was stopped with actinomycin D (5 µg/ml) (Sigma).  Cells were collected before 
actinomycin D and at various time points after the addition of Actinomycin D.     
 
RNA isolation and conversion to cDNA 
The RNA was isolated from the macrophages with the RNAqueous-4 PCR kit 
(Ambion).  RNA (13.2µl/PCR reaction) was then converted to cDNA with the High 
Capacity cDNA Reverse Transcription kit using the included RT random primers 
(Applied Biosystems).  The RT PCR cycles were 25°C for 10 min, 37°C for 120 min, and 
85°C for 5 min. 
 
Measurement of RNA decay rate 
The RT PCR product was purified using the QIAquick PCR purification kit 
(Qiagen).  Quantitative PCR was then performed on the purified cDNA using SYBR 
green master mix (Applied Biosystems) to detect TNFα cDNA.  Each reaction mixture 
contained 10 µl 2x SYBR green master mix (Applied Biosystems), 1 µl primer-F (mSP-
TNFα-F: 5’-GATTATGGCTCAGGGTCCAA-3’ or mSP-GAPDH-F: 5’-
CCACCCAGAAGACTGTGGAT-3’) (1µM), 1 µl primer-R (mSP-TNFα-R: 5’-
CTCCCTTTGCAGAACTCAGG-3’ or mSP-GAPDH-R: 5’-
CACATTGGGGGTAGGAACAC-3’) (1 µM), 6 µl H2O, and 2 µl cDNA.  The QPCR 
cycles were stage 1 (50°C for 2 min) once, stage 2 (95°C for 10 min) once, stage 3 (95°C 
for 15 seconds then 60°C for 1 minute) 40 times, then stage 4 (dissociation stage) (95°C 
for 15 seconds, 60°C for 1 minute, 95° for 15 seconds, 60°C for 15 seconds) once.  
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GAPDH was measured as the internal control gene.  The Ct values were then converted 
into relative levels of TNFα mRNA normalized to GAPDH at the different time points 
after the addition of actinomycin D.   
 
Transfection paradigm for measuring rate of mRNA decay 
293 T cells were cultured in DMEM (Gibco) with 10% FBS (Gibco), and 1% 
penicillin/streptomycin.  To make the lenti-virus containing the human HSPB1 gene, the 
293 T cells were transfected with MDL, REV, VSV-G (viral genes), and a pBOB vector 
(Addgene) containing either the wild-type HSPB1 or mutant HSPB1 gene for 6 hours.  
The supernatant containing the virus was collected over 3 days.  The virus was pelleted 
and resuspended in PBS with 10% glycerol.  The macrophages were then transfected with 
the virus containing the mutant or wild-type HSPB1 gene for 40 hours. 
 
Western Blot 
The macrophages were harvested after the transfection and centrifuged at 1200 
rpm for 10 minutes at room temperature. The cell pellets were resuspended in RSB-100 + 
0.1% NP40.  The cells were lysed via sonication and centrifuged at 14000 rpm for 15 
minutes at 4°C.  The cytoplasmic extracts were then used for the immunoblot and loaded 
into each lane of the polyacrylamide gel.  The proteins were separated via sodium 
dodecyl sulfate polyacrylamide gel electrophoresis and transferred to a nitrocellulose 
membrane. The membrane was blocked with 3% BSA + 0.1Tx-100 in PBS.  All 
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antibodies were diluted in blocking solution.  GAPDH was used as the loading control.  
The bands were visualized with a LI-COR Odyssey Infrared Imager. 
 
Transgenic Mice  
The open reading from M13-HSPB1 (GeneCopoeia, Rockville, MD) was cut out 
of the HSPB1 gene and ligated into a MoPrP.Xho vector via digestion with XhoI [16].  
Restriction endonuclease digestion was used to map the HSPB1 insert in the vector.  
DNA sequencing of the insert was used to determine its orientation (primers: forward: 5’- 
TACCCGCATAGCCGCCTCTT-3’, reverse: 5’-GATGGTGATCTCGTTGGACT-3’). 
To linearize the vector with the insert, NotI was used to digest the vector, which was then 
purified via agarose gel chromatography.  The digested and linear DNA was injected into 
fertilized oocytes, according to the standard techniques used at the Transgenic Animal 
Facility at The Ohio State University, Columbus, OH.  PCR was used to determine which 
mice contained the HSPB1 transgene (PrP-HSPB1 primers: Forward 5’-
CACTGGCTGATGACAGACTC-3’; Reverse 5’- CCGGTGTGGACCCCACCCAA-3’).  
The HSPB1(R136W) transgene was developed by making a single nucleotide substitution 
(C406T) with a commercially available kit (Stratagene, La Jolla, CA).  Mice were cared 
for according to the Principles of Laboratory Animal Care (National Institutes of Health 
publication number 86-23) and the Ohio State University animal care committee 
guidelines. 
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Immunohistochemistry  
Mice were anesthetized and perfused first with PBS, then with 4% 
paraformaldehyde in PBS.   The sciatic nerve and lumbar sections of the spinal cord were 
removed and fixed in 4% paraformaldehyde in PBS at 4°C overnight.  Transverese-free-
floating sections 40 µm thick were sectioned with the Vibrotim 3000.  The sections were 
blocked in 10% donkey serum in 0.1% Triton X-100 in PBS at room temperature for 2 
hours.  Then, the sections were incubated in diluted primary antibody at 4°C overnight.  
The sections were then incubated in a 1:200 dilution of Alexa Fluor ® secondary 
antibodies (Invitrogen, Carlsbad, CA) at room temperature for 2 hours.  Primary and 
secondary antibodies were diluted in 10% donkey serum in 0.1% Triton X-100 in PBS.  
0.1M PBS was used to rinse the sections.  The sections were coverslipped with 
Immumount (Thermo Scientific, Pittsburgh, PA).  A Zeiss LSM510-META confocal 
laser-scanning microscope (Zeiss, Thornwood, NY) was used to take images. 
 
Electrophysiology 
Conduction studies of the caudal tail nerve and sciatic motor nerve were 
conducted as previously described [17].  Mice were anesthetized via interperitoneal 
injection of 100 mg/kg ketamine + 10 mg/kg xylazine (Sigma-Aldrich, St. Louis, 
Missouri).  The distal back and hindlimbs of the mice were shaved.  Hair-removal cream 
removed excess fur not removed via shaving. Water and alcohol were used to clean the 
exposed skin.  Mice were restrained with tape on a piece of styrafoam with their 
hindlimbs extended at the knees and abducted at the hips. Disposable 27G needle 
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electrodes (Ambu USA, Glen Burnie, Maryland) were used to stimulate the mice and ring 
electrodes (Alpine Biomed, Skoylunde, Denmark) were used to record the electrical 
conduction.  The mice were grounded through their tail via a disposable disc surface 
electrode, (Ambu USA, Glen Burnie, Maryland).  A portable electrodiagnostic system 
(Synergy EMG machine version 9.1, Oxford Instruments, Abingdon, UK) was used to 
perform motor nerve conduction studies NCS. An LCD monitor (Toshiba Northa 
America, Houston, Texas) was used to show the waveforms.  The high and low pass 
filters were set at 10 kHz and 0 Hz, respectively.  The recording ring electrodes were 
coated with electrode gel (Spectra 360 by Parker laboratories, Fairfield, New Jersey) and 
placed at the base of the tail for tail motor NCS. The reference electrode was 10 mm 
distal to the ring electrode.  The cathode used for stimulation was inserted 2-3 mm deep.  
This cathode was place 5 mm proximal to the recording electrodes and 3-5 mm lateral to 
the midline in order to generate distal responses.  It was then moved 7 mm away from the 
distal stimulating point to generate proximal responses.  The anode was placed 
subcutaneously in the skin overlying the sacrum.  0.1-ms single square-wave pulses 
stimulated the nerve.  Gradually, supramaximal responses were generated, and maximal 
responses were obtained with stimulus currents of less than 10 mA.  A tape measure was 
used to measure the distance between the proximal and distal sites of stimulation.  
Sensitivity of 20 mV/division and sweep speed of 2 ms/division were used to gather the 
data.  For every studied nerve, the distal latency, distal and proximal compound motor 
action potential (CMAP) amplitudes, distal and proximal CMAP durations (measured 
from onset of initial negative deflection to initial return to baseline), and conduction 
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velocity were measured.  To study the contralateral side, the electrodes used for 
stimulation were moved without altering the position of the recording electrodes.  For the 
sciatic nerve (ScN) motor NCS, the active recording ring electrode was placed over the 
gastrocnemium muscle with the reference electrode over its tendon.  The stimulating 
cathode was placed 5 mm proximal to the recording electrode in the midline of the 
posterior thigh and 6 mm proximally in the medial gluteal region to obtain distal and 
proximal responses, respectively. The anode was placed subcutaneously in the midline 
over the sacrum. The mice were stimulated, and electrophysiological data were acquired 
as described previously for the tail motor NCS.  
 
Behavioral testing 
The mice were weighed monthly for 1 year.  Their hindlimb muscle strength was 
also tested monthly for 1 year by holding them by the tail and observing the spread of 
their hind limbs due to reflex.  At 6 months old, the mice were placed in an open field 
Digiscan Activity Monitor (Accuscan, Columbus, OH) for 2 hours.  The motion and 
activity of the mice was measured by the Accuscan software according to breaks in 16 
light beams on the horizontal X and Y plane.  To measure leg weakness and to determine 
how the transgenes affected the gait of the mice, the footprints of the mice were analyzed.  
The hind paws were painted with ink.  Then, the mouse was placed in a wooden corridor 
(6 cm x 40 cm) where they walked from beginning to end on a sheet of paper as 
described [18, 19].  The toe spread (TS) (the distance between the 1
st
 and 5
th
 toes), the 
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inter-toe spread (IT) (the distance between the 2
nd
 and 4
th
 toes), and the paw length (PL) 
of the footprints were measured. 
 
Transfection paradigm for subcellular localization of HSPB3 and HSPB3(R7S) 
HeLa cells were grown in minimum essential media (Gibco) with 10% fetal 
bovine serum (Gibco), 1% penicillin-streptomycin solution (Fisher), and 1% non-
essential amino acids (Gibco).  HeLa cells were seeded onto cover slides and grown over 
night to 70% confluency.  The cells were then transiently-transfected with a pmaxGFP 
vector (Lonza) containing the green fluorescent protein gene or with a PCDNA/4TO 
vector that contained the flag-tagged HSPB3 gene, the flag-tagged HSPB3(R7S) gene, or 
the flag-tagged HSPB1 gene. The cells were transfected with the FuGENE HD 
transfection reagent (Roche) for 17 hours.   
 
Immunofluorescence for subcellular localization of HSPB3 and HSPB3(R7S) 
After transfection, the cells were fixed with 1% formaldehyde for 30 minutes and 
blocked with 4%BSA+0.5%TritonX-100 in PBS.   Mouse-anti-flag antibody (Sigma) was 
the primary antibody and anti-mouse-Alexa Fluor-488 antibody (Invitrogen) was the 
secondary antibody.  All antibodies were diluted in 4%BSA+0.1%TritonX-100 in PBS.  
Images were taken with a confocal microscope (courtesy of Dr. Raphael-Fortney). 
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Calculations 
Primer Efficiencies 
Primer efficiencies were determined from the slope of the standard curve.  Seven 
serial dilutions of cDNA harvested from stimulated macrophages before the addition of 
actinomycin D were used to make the standard curve.  Quantitative PCR was performed 
on the serial dilutions of cDNA using the QPCR reaction mixtures and cycles as stated 
above.  The Ct values were plotted versus the dilution factor on a logarithmic scale to 
determine the standard curve.  A logarithmic regression line was fitted to the plotted Ct 
values.  The slope was used to determine the primer efficiencies according to the 
equation: Efficiency = 10
(-1/slope).
 
 
Determination of mRNA levels and mRNA half life 
QPCR was performed on the cDNA isolated at different time points post-addition 
of actinomycin D as state above.  QPCR was used to quantitate the levels of TNFα cDNA 
and GAPDH cDNA.  GAPDH was used as the internal control.  TNFα was used to 
determine the rate of ARE-mediated mRNA decay.  Since TNFα is endogenously 
expressed in macrophages and has an ARE on its mRNA, measurement of TNFα mRNA 
is an ideal mRNA to detect when studying ARE-mediated mRNA decay.  The Ct values 
were converted to fold changes of mRNA over time post-actinomycin D for either TNFα 
or GAPDH according to the equation: Fold Change = efficiency
(Ct at time 0)-(Ct at time t)
 where 
time t is hours post-addition of actinomycin D, and time 0 is the time at which 
actinomycin D was added.  The TNFα fold changes were normalized to GAPDH by 
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dividing the fold change of TNFα mRNA by the fold change of GAPDH mRNA for the 
same time point.  The comparison of this ratio at different time points represented the 
relative levels of TNFα mRNA at those time points.  The scatter plot of the relative levels 
of TNFα mRNA was fitted with an exponential regression equation of the form: y=y0e
-kt
.  
The half lives of TNFα mRNA under different conditions were calculated according to 
the equation: t1/2=ln2/k.  
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Chapter 3 
 
Results 
Aim 1.To determine the effect of HSPB1 mutations on ARE-mediated mRNA decay 
Harvesting Macrophages 
After bone marrow cells were harvested from mice and cultured for 10 days, we 
determined that these cultured cells were macrophages by detection of cd11b (Figure 4).  
Cd11b is the alpha chain of the Mac-1 leukocyte integrin heterodimer [20].  Cd11b is an 
adhesion molecule that is expressed at high levels in macrophages, monocytes, and 
neutrophils, but is either not detectable or has very low expression in myeloid precursor 
cells [20].  Therefore, we used cd11b as a macrophage marker. 
 
 
 
 
  
Figure 4. Cultured mouse bone marrow cells are macrophages.   
Bone marrow cells were harvested from mice and cultured for 10 days.  The bone marrow cells were then 
harvested and a western blot was performed on these cells to confirm that they were macrophages via 
detection of cd11b.   The primary antibody was rabbit-anti cd11b (abcam 1:1000 dilution).  The secondary 
antibody was goat-anti rabbit (Odyssey; 1:10000 dilution). 
HSPB1 
(R136W) 
Transfection 
No 
transfection 
WT HSPB1 
Transfection 
+ 
CTRL 
Weight 
Marker 
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Development of the RNA decay assay 
To develop the RNA decay QPCR assay, a standard curve was made with serial 
dilutions of cDNA.  The primer efficiencies were calculated from the standard curve to 
be 4.73888 for the TNFα primers and 4.753878 for the GAPDH primers (Figure 2 and 
Table 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Primers  Slope  Primer Efficiency  
TNFα -1.48  4.73888  
GAPDH  -1.477  4.753878  
Table 1. TNFα and GAPDH primer efficiencies.   
The slope of the regression line of the standard curve was used to calculate the efficiency of each primer pair 
according to the equation: efficiency = 10-1/slope. 
y = -1.48Ln(x) + 18.303
R2 = 0.9805
y = -1.477Ln(x) + 18.622
R2 = 0.97990
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Figure 5.  Standard curve for QPCR primers.  
1.83x105 macrophages/well were plated into 6 well plates and left overnight.  The macrophages were 
stimulated with LPS (1 µg/ml) for 2 hours and then collected.  RNA was isolated and converted to cDNA. 
Quantitative PCR was then performed on seven serial dilutions of cDNA to make a standard curve.  
Standard curves were made for the TNFα primers (the experimental gene) and GAPDH primers (the 
internal control gene). 
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Since, TNFα is endogenously expressed in macrophages and has an ARE on its 
mRNA, measurement of TNFα mRNA is an ideal mRNA to detect when studying ARE-
mediated mRNA decay.  To determine the rate of TNFα mRNA decay, and thus the rate 
of ARE-mediated mRNA decay, macrophages were stimulated for 2 hours with LPS 
(1µg/ml), actinomycin D (5µg/ml) (Sigma) was added to stop transcription, the 
macrophages were harvested at the indicated time points, and the rate of decay of TNFα 
mRNA was determined.  After transcription was stopped, the TNFα mRNA decayed over 
time as shown by the gradual decline in relative levels of TNFα mRNA for the 
actinomycin D data in Figure 6.  The half life of TNFα mRNA was calculated to be 16.94 
minutes when actinomycin D was added.  The half life of TNFα mRNA was calculated to 
be -84.9 minutes when actinomycin D was not added.  We were able to confirm that a 
function of actinomycin D is to stop transcription.  Upon the addition of actinomycin D, 
the relative level of TNFα mRNA decreased because no new TNFα mRNA was being 
transcribed and the TNFα mRNA that was present decayed normally.  However, when 
actinomycin D was not added, the levels of TNFα mRNA did not decrease because the 
natural decay of TNFα mRNA was being offset by the transcription of new TNFα 
mRNA. 
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ARE-mediated mRNA decay in macrophages transfected with mutant or wild-type 
HSPB1 
Macrophages were transfected with either the wild-type HSPB1 gene or the 
mutant HSPB1(R136W) gene (Figure 7).  To date, we have had difficulties obtaining a 
robust transfection efficiency and have been unable to address the effect of mutant 
HSPB1 on ARE-dependent mRNA decay in macrophages. 
Figure 6. Actinomycin D confirmed to inhibit transcription, allowing the rate of mRNA decay to be measured.   
1.83x105 macrophages/well were plated into 6 well plates and left overnight.  The cells were stimulated with LPS (1 
µg/ml) for 2 hours.  Then transcription was stopped with Actinomycin D (5 µg/ml). Macrophages were collected before 
the addition of actinomycin D (time 0), and 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, and 2 hours after 
the addition of actinomycin D.  Control macrophages (with no Actinomycin D) were stimulated with LPS and collected 
simultaneously.  RNA was isolated and converted to cDNA which was quantitated via QPCR.  Fold changes of TNFα 
cDNA over time were normalized to fold changes of GAPDH over time.  This ratio represented the relative levels of 
TNFα mRNA at the indicated time points.  The half life of TNFα mRNA with or without the addition of actinomycin D 
was calculated from the exponential regression equation.   
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40 hours post-transfection, the mRNA decay assay was performed on these cells 
(Figure 8).  The half-life of TNFα mRNA was calculated to be 43.5 minutes for 
untransfected macrophages, 7.81 minutes for macrophages transfected with the wild-type 
HSPB1 gene, and 8.87 min for macrophages transfected with the HSPB1(R136W) gene.   
 
 
 
 
 
 
 
 
 
Figure 7. Unsuccessful lenti-viral transfection of macrophages with HSPB1 and HSPB1(R136W). 
1.7x105 mouse macrophages/well were transfected with a lenti-viral vector containing a wild-type 
HSPB1 gene or a mutant HSPB1(R136W) gene.  40 hours post-transfection, the cells were harvested for 
a western blot to determine if the exogenous HSPB1 and HSPB1(R136W) were expressed.  GAPDH 
was detected as a loading control.  The primary antibodies were mouse-anti Hsp27 (abcam; 1:500 
dilution) for HSPB1 and mouse-anti GAPDH (Ambion; 1:4000 dilution.)  The secondary antibody was 
goat-anti mouse (Odyssey; 1:10000 dilution). 
HSPB1 
(R136W) 
Trans-
fection 
No 
transfection 
WT  
HSPB1 
Transfection 
+ 
CTRL 
Weight 
Marker 
GAPDH 
HSPB1 
27 
 
y = 0.4564e-0.955x
R² = 0.1745; t1/2=43.5 min
y = 0.0716e-5.327x
R² = 0.7193; t1/2=7.81 min
y = 0.2063e-4.69x
R² = 0.8875; t1/2 = 8.87 min
0.00001
0.0001
0.001
0.01
0.1
1
10
0 0.5 1 1.5 2
R
e
la
ti
ve
 le
ve
l o
f 
TN
fa
 m
R
N
A
Time Post Actinomycin D (hrs)
Stimulation of Transfected Macrophages
untransfected
B1
R136W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim 2:  To determine whether ARE-mediated mRNA decay is altered in vivo 
Expression and localization of HSPB1 and HSPB1(R136W) transgenes 
To complete this Aim, our laboratory created novel transgenic mouse lines 
expressing wild-type HSPB1 or mutant HSPB1.  HSPB1 and HSPB1(R136W) were 
expressed in both the brain and the spinal cord, including the ventral horn of the spinal 
cord in ChAT-positive neurons, with no apparent difference in subcellular localization 
between mutant and wild-type HSPB1 (Figure 9).  Neither wild-type HSPB1 nor 
Figure 8.  TNFα mRNA decay of cells transfected with HSPB1 or HSPB1(R136W) genes. 
1.7x105 macrophages/well were plated into 6 well plates and left overnight.  The macrophages were 
transfected with a lenti-viral vector containing the HSPB1 gene or the HSPB1(R136W) gene.  
Untransfected cells were used as a control.  40 hours post-transfection, the cells were stimulated with LPS 
(1 µg/ml) for 2 hours.  Then transcription was stopped with Actinomycin D (5 µg/ml). Macrophages were 
collected before the addition of actinomycin D (time 0), and 5 minutes, 15 minutes, 30 minutes, and 1.5 
hours after the addition of actinomycin D.  RNA was isolated and converted to cDNA which was 
quantitated via QPCR.  Fold changes of TNFα cDNA over time were normalized to fold changes of 
GAPDH over time.  This ratio represented the relative levels of TNFα mRNA at the indicated time points.  
The half life of TNFα mRNA was calculated from the exponential regression equations.   
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HSPB1(R136W) was expressed in glial cells of the spinal cord, indicating that the PrP 
promoter is neuronal-specific.  Interestingly, expression of wild-type HSPB1 was lower 
than the expression of HSPB1(R136W) in both brain and spinal cord. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Expression of HSPB1(R136W) and HSPB1 transgenes. 
A) Both the HSPB1 and HSPB1(R136W) transgenes (green) are expressed in the ventral horn of the 
spinal cord in ChAT positive neurons (red).  Neither transgene is expressed in glial cells (blue).  
Nontransgenic FVB mice do not express HSPB1 in neurons or glial cells (Courtesy Dr. Amit 
Srivastava.)  B) Brain and spinal cord samples were harvested from HSPB1 and HSPB1(R136W) 
transgenic mice.  Samples were also harvested from non-transgenic mice as a control.  Expression of 
HSPB1 or HSPB1(R136W) was detected via western blot. The primary antibodies were rabbit-anti 
Hsp27 (abcam; 1:1000 dilution) for HSPB1 and mouse-anti-GAPDH (ambion; 1:4000 dilution).  The 
secondary antibodies were goat-anti mouse (Odyssey; 1:10000 dilution) and goat-anti rabbit (Odyssey; 
1:10000 dilution) (Courtesy Samantha Renusch). 
B 
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Because dHMN caused by sHSP mutations is an axonal neuropathy in humans, 
we wanted to show if in our model, the expressed wild-type HSPB1 and HSPB1(R136W) 
proteins were transported from the motor neuron cell body to the axons of the peripheral 
nervous system.  In both transgenic animals, wild-type and mutant HSPB1 showed co-
localization with neurofilaments showing that these proteins are transported to axons in 
the peripheral nervous system (Figure 10).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.  Co-localization of wild-type HSPB1 and HSPB1(R136W) with neurofilaments. 
Wild-type and mutant HSPB1 (green) are expressed in neurofilament-containing neurons (red) in the 
sciatic nerves from transgenic mice.  Scale bar, 50µm.  (Courtesy Dr. Amit Srivastava.) 
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HSPB1(R136W) leads to a decrease in axonal conduction 
To determine if HSPB1(R136W) led to an axonal or a demyelinating neuropathy, 
electrophysiolocial studies were conducted on the transgenic mice at 6 months and 1 year 
of age (Figure 11.)  At 6 months, there were no statistically significant differences 
between sciatic motor amplitudes of the non-transgenic control, transgenic HSPB1, or 
transgenic HSPB1(R136W) mice.  At 1 year old, the transgenic HSPB1(R136W) showed 
a statistically significant decrease in sciatic motor amplitude (p<0.05) compared to 
transgenic HSPB1 and non-transgenic mice.  However, there was no statistically 
significant difference in the conduction velocity of the HSPB1 transgenic, 
HSPB1(R136W) transgenic, or non-transgenic mice.  This indicates that the transgenic 
HSPB1(R136W) mice developed an axonal neuropathy by 1 year of age.   
 
 
 
 
 
 
 
 
 
 
Figure 11.  Electrophysiology of transgenic mice. 
A) Waveforms of electrophysiological stimulation of non-transgenic control, transgenic 
PrP-HSPB1(R136W), and transgenic PrP-HSPB1 mice at 1 year of age.  B) Quantitation of 
amplitude and conduction velocity of electrophysiological waveforms in A (Courtesy Dr. 
David Arnold).  N=5 for each group of mice. 
A 
B 
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Behavioral analysis 
There was no significant difference in the mortality rate of transgenic 
HSPB1(6.53% mortality), transgenic HSPB1(R136W) (6.11% mortality), and 
nontransgenic (9.31% mortality) mice.  An open field Plexiglas chamber with light 
sensors was used to measure the motion and activity of the mice.  The behavior of the 
transgenic HSPB1, transgenic HSPB1(R136W), and non-transgenic mice were not 
significantly different at 6 months of age (Table 2). 
 
 Prp-HSPB1 Prp-HSPB1(R136W) FVB/NJ p-value 
Total distance (cm.) 9330 ± 6197 20718± 47224 26540 ± 43136 0.81 
Rest time (sec.) 5376 ± 1403 5378± 1173 5255 ± 1354 0.93 
Movement time (sec.) 1823 ± 1402 1820 ± 1173 1944 ± 1354 0.93 
Sterotypy count 565 ± 465 560 ± 377 547 ± 416 0.99 
Vertical activity time (sec.) 1031 ± 863 573 ± 370 559 ± 424 0.3 
Vertical activity count 2110 ± 1224 1481 ± 912 1538 ± 1203 0.72 
Wheel rotations 1130 ± 985 408 ± 432 667 ± 818 0.17 
Table 2.  Difference in behavior among transgenic HSPB1, transgenic HSPB1(R136W), and non-
transgenic mice. 
At 6 months of age, transgenic HSPB1, transgenic HSPB1(R136W), and nontransgenic mice were placed 
in an open field activity box for 2 hours.  Different parameters describing the behavior and activity of the 
mice were measured.  Data expressed as mean ± S.D. One-way ANOVA. p<0.05 is considered significant. 
N=24 for non-transgenic control mice; N=27 for PrP-HSPB1(R136W) mice; N=2 for PrP-HSPB1 mice. 
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The footprints of 1 year old mice were measured and analyzed.  There was no 
statistically significant difference between mutant PrP-HSPB1(R136W), wild-type PrP-
HSPB1, or non-transgenic mice toe spread, inter-toe spread, or paw length (Figure 12). 
 
 
 
 
 
 
 
 
 
 
 
 
Aim 3: To determine whether ARE-mediated mRNA decay is altered by the expression of 
HSPB3 
Little is known about the function of wild-type HSPB3.  To begin to characterize 
both wild-type and mutant HSPB3, we determined the subcellular localization of HSPB3 
and HSPB3(R7S).  We transiently transfected HeLa cells with either PCDNA4/TO-FB3, 
PCDNA4/TO-FR7S, PCDNA4/TO-FB1, or pmaxGFP and then performed 
immunofluroescence on the cells (Figure 13).  HSPB1 is known to be a cytoplasmic 
Figure 12. Foot print analysis of 1 year old nontransgenic, transgenic HSPB1, and transgenic 
HSPB1(R136W) mice. 
Toe spread (TS), inter-toe spread (ITS), and paw length (PL) of 1 year old nontransgenic, transgenic 
HSPB1, and transgenic HSPB1(R136W) mice were measured.  There was no statistically significant 
difference between nontransgenic, transgenic HSPB1, and transgenic HSPB1(R136W) foot prints. N=5 
for each group of mice. 
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protein, and since HSPB1 is homologous to HSPB3, we wanted to compare the 
subcellular localization of HSPB3 to HSPB1 [21].  We used GFP as a transfection control 
to show that our transfection procedure was working.  GFP was successfully expressed 
throughout the cells (Figure 13A).  We preliminarily confirmed that HSPB1 is a 
cytoplasmic protein (Figure 13B).  However, our preliminary results showed that HSPB3 
and HSPB3(R7S) are localized in the nucleus, but not in the nucleolus (Figure 13C, 
13D).  There was no significant difference between the subcellular localization of HSPB3 
and HSPB3(R7S) (Figure 13C, 13D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HSPB3 is very difficult to transfect.  As a result, the other preliminary experiments of 
HSPB3 expression were unsuccessful, and we did not have time to perform the ARE-
Figure 13. Subcellular localization of mutant and wild-type HSPB3. 
 
Immunofluorescence of HeLa Cells transiently transfected with pmaxGFP or with the pcDNA4/TO 
vector containing flag-tagged genes for HSPB1, HSPB3, or HSPB3(R7S).  The green shows GFP 
and the anti-flag antibody which recognized HSPB1, HSPB3, and HSPB3(R7S).  A) HeLa cells 
transfected with pmaxGFP containing the GFP gene.  B) HeLa cells transfected with pcDNA4/TO-
FB1 containing the flag-tagged HSPB1 gene.  C) HeLa cells transfected with pcDNA4/TO-FB3 
containing the flag-tagged HSPB3 gene.  D) HeLa cells transfected with pcDNA4/TO-FR7S 
containing the flag-tagged HSPB3(R7S) gene. 
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mediated mRNA decay assay with macrophages expressing the HSPB3 or HSPB3(R7S) 
genes.  
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Chapter 4 
 
Discussion 
Aim 1.To determine the effect of HSPB1 mutations on ARE-mediated mRNA decay 
We successfully developed an assay to measure the rate of mRNA decay (Figure 
6).  When actinomycin D was added to the macrophages, the TNFα mRNA decayed over 
time because transcription was inhibited.  Without the addition of actinomycin D, the 
levels of TNFα mRNA did not decrease, as shown by a negative half-life, because TNFα 
mRNA was being continuously transcribed.   
The results of the mRNA decay assay on the macrophages transfected with the 
HSPB1 gene or the HSPB1(R136W) gene were inconclusive.  Expression of HSPB1 and 
HSPB1(R136W) was not detected in the western blot of the transfected macrophages, 
indicating that the transfection was unsuccessful (Figure 7).  Also, HSPB1 and 
HSPB1(R136W) cDNA from transfected macrophages was not detected by QPCR (data 
not shown).  However, the half-life of TNFα mRNA of the untransfected macrophages 
was over 5 times higher than that of the macrophages transfected with the HSPB1 or 
HSPB1(R136W) genes. Based on the failure of the western blot and QPCR to detect 
HSPB1 and HSPB1(R136W) protein and cDNA, respectively, it would seem that the 
transfection was unsuccessful.  The transfection efficiency may have been too low to 
detect via western blot and QPCR.  Therefore, when the transfection is repeated, a more 
sensitive method of protein expression detection, such as immunofluorescence staining, 
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should be used to detect HSPB1 and HSPB1(R136W) expression to determine the 
transfection efficiency.  
If the case was that the transfection efficiency was too low to be detected via 
western blot and QPCR, but low levels of HSPB1 and HSPB1(R136W) were expressed, 
the results indicate that HSPB1(R136W) did not have an inhibitory effect on ARE-
mediated mRNA decay because there was little difference between the TNFα mRNA half 
lives in macrophages transfected with wild-type HSPB1 and macrophages transfected 
with HSPB1(R136W).  However, the half-life of TNFα mRNA was slightly higher in 
macrophages transfected with the HSPB1(R136W) gene than in macrophages transfected 
with the wild-type HSPB1 gene.  This could indicate that HSPB1(R136W) does have an 
inhibitory effect on ARE-mediated mRNA decay, but the expression of HSPB1 and 
HSPB1(R136W) was too low to show the difference because of the poor transfection 
efficiency. 
Another possibility to explain this contradiction is that the lenti-viral transfection 
reagents may have had an unanticipated effect on the mRNA decay machinery despite the 
lack of HSPB1 and HSPB1(R136W) expression.  This would explain why there was a 
huge difference between the half-lives of TNFα mRNA of the transfected and 
untransfected macrophages, but little difference in half-lives between the macrophages 
transfected with the wild-type HSPB1 gene and those transfected with the 
HSPB1(R136W) gene.  When this experiment is repeated the untransfected control 
macrophages should be infected with an empty lenti-viral vector to control for this 
unanticipated effect.  
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Also, the R
2
 values for the exponential regression equations were all significantly 
less than 0.9.  Therefore, the calculated half-lives may not be accurate.  This experiment 
must be repeated multiple times until the data is reproducible and the R
2
 values are closer 
to 1 before conclusions can be drawn about the affect of HSPB1(R136W) on ARE-
mediated mRNA decay in vitro.    
 
Role of ARE-mediated mRNA decay in other MNDs 
All MNDs are related and are characterized by muscle weakness and motor 
neuron death.  Because MNDs have related clinical phenotypes, we hypothesize that a 
common pathway is altered in all MNDs.  Specifically, because ARE-mediated mRNA 
decay is implicated in dHMN, and other alterations of RNA processing are implicated in 
ALS, SMA, and lethal congenital contracture syndrome (LCCS) [3], we hypothesized 
that mRNA processing is altered in all MNDs.  To determine if ARE-mediated mRNA 
decay, a specific type of mRNA processing, is affected in MNDs other than dHMN, we 
performed the ARE-mediated mRNA decay assay as described in Aim 1 on macrophages 
from a well established mouse model of ALS, in which there is a G93A mutation in 
superoxide dismutase 1 (SOD1) (courtesy of Dr. Glenn Lin) [22].  The SOD1 G93A 
mouse model is the most commonly used mouse model of ALS [23] (Figure 12).  The 
wild-type mice had a TNFα mRNA half life of 13.4 minutes.   The mutant G93A mice 
had a TNFα mRNA half life of 13.81 minutes.  This indicates that ARE-mediated mRNA 
decay is not altered in this model of ALS; however, these results are only from one 
experiment, and are therefore preliminary.  
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In addition, the R
2
 values for the exponential regression equations were below 
0.6, possibly due to the presence of outliers.  Therefore, this experiment must be repeated 
multiple times and further analyses must be done before conclusions can be made about 
the role, or lack thereof, of ARE-mediated mRNA decay in this model of ALS.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim 2: To determine whether ARE-mediated mRNA decay is altered in vivo 
Both wild-type HSPB1 and HSPB1(R136W) were expressed in the brain, and 
spinal cord, including the ventral horn of the spinal cord.  There was no significant 
Figure 14. ARE-mediated mRNA decay is not inhibited in mouse model of ALS. 
Macrophages were harvested from 2 wild-type mice and 2 mice containing the G93A mutation in SOD1 
from a mouse model of ALS.  2.5x105 macrophages/well were plated into 6 well plates and left overnight.  
The cells were stimulated with LPS (1 µg/ml) for 2 hours.  Then transcription was stopped with 
Actinomycin D (5 µg/ml). Macrophages were collected before the addition of actinomycin D (time 0), and 
5 minutes, 15 minutes, 30 minutes, 1 hour, and 2 hours after the addition of actinomycin D.  RNA was 
isolated and converted to cDNA which was quantitated via QPCR.  Fold changes of TNFα cDNA over time 
were normalized to fold changes of GAPDH over time.  This ratio represented the relative levels of TNFα 
mRNA at the indicated time points.  The half life of TNFα mRNA was calculated from the exponential 
regression equation 
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difference in subcellular localization between the wild-type and mutant HSPB1 protein.  
Both proteins were expressed in neurons of the spinal cord, but neither protein was 
expressed in glial cells of the spinal cord indicating that the PrP promoter limited 
transgene expression to neurons.   
Both HSPB1 and HSPB1(R136W) showed co-localization with neurofilaments 
indicating that these proteins were being transported from the motor neuron cell bodies to 
the axons.  This localization combined with the statistically significant decrease in sciatic 
motor amplitude of PrP-HSPB1(R136W) 1 year old mice compared to PrP-HSPB1 or 
non-transgenic control 1 year old mice indicates that the PrP-HSPB1(R136W) mice 
develop an axonal neuropathy.  In addition, there was no statistically significant 
difference between conduction velocity of these mutant mice compared to wild-type and 
non-transgenic control mice.  A difference in conduction velocity would have suggested a 
demylinating neuropathy unlike that seen in dHMN patients with sHSP mutations.  
However, this was not the case, further supporting the conclusion that these PrP-
HSPB1(R136W) mice developed an axonal neuropathy.  
Because there was no significant difference in the localization of HSPB1 
expression between the two transgenic lines, and because there was little difference in 
behavior or gait between the mutant transgenic mice, the wild-type transgenic mice, and 
the non-transgenic mice, the axonal neuropathy developed was mild and subclinical, 
unlike that seen in patients.  One reason that these mice did not develop a severe, clinical 
neuropathy may be that we used a prion-protein promoter to limit expression of the 
transgene to neurons.  In patients, the sHSP mutations are expressed ubiquitously.  In 
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patients, the HSPB1(R136W) expressed in non-neuronal cells may affect motor neurons 
in a non-cell autonomous manner.  Therefore, HSPB1(R136W) may not have been 
expressed at high enough levels in non-neuronal cells for the development of a severe 
clinical neuropathy.  This type of non-cell autonomous effect of non-neuronal cells on 
motor neurons is seen in the SOD1 model of ALS [24-26].  Another possibility as to why 
these PrP transgenic mice did not develop a clinical neuropathy may be that the 
endogenous mouse HSPB1 homolog, Hsp 25, was compensating for the harmful effects 
of the mutant HSPB1(R136W).   
In order to determine whether ARE-mediated mRNA decay is affected in vivo in a 
model for dHMN, ARE-mediated mRNA decay must be measured directly from our 
mouse model of dHMN.  Ideally, a transgenic HSPB1 mouse that exhibits a more severe 
phenotype would permit more confidence that any alterations in mRNA decay that may 
be found are related to the neuropathy.  
 
Aim 3: To determine whether ARE-mediated mRNA decay is altered by the expression of 
HSPB3 
We were able to show the subcellular localization of HSPB3 and HSPB3(R7S).  
Our preliminary results confirmed that HSPB1 is a cytoplasmic protein and showed that 
HSPB3 and HSPB3(R7S) are nuclear proteins; however, HSPB3 and HSPB3(R7S) are 
not localized in the nucleolus.  Since both HSPB3 and HSPB3(R7S) were found to be 
localized in the nucleus but not the nucleolus, we preliminarily concluded that the R7S 
mutation does not have a significant effect on the subcellular localization of HSPB3.  The 
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localization of the proteins was visibly clear in the cells; however, we only conducted one 
trial.  More trials must be conducted to confirm our results.   
Our subsequent experiments with HSPB3 and HSPB3(R7S) were unsuccessful.  
Transfected HSB3 and HSPB3(R7S) have proven difficult to express via chemical 
transfection with the FuGENE HD transfection reagent (Roche) or a Qiagen kit.  
Therefore, we are currently developing a lenti-viral transfection vector to transfect the 
HSPB3 and HSPB3(R7S) genes.  If this is not successful, other transfection mechanisms 
must be tried to determine how best to transfect exogenous HSPB3 and HSPB3(R7S) 
genes into macrophages or some other cell type that endogenously expresses TNFα.  
 
Future Directions 
To determine if HSPB1(R136W) has an inhibitory affect on ARE-mediated 
mRNA decay in vitro, the mRNA decay assay described in Aim 1 must be repeated.  
Currently, we are studying the effect of HSPB1(R136W) on ARE-mediated mRNA decay 
of an endogenously expressed ARE-containing mRNA.  Therefore, we also aim to 
determine if HSPB1(R136W) affects ARE-mediated mRNA decay of an exogenous 
ARE-containing mRNA.  To study this, we will double transfect the macrophages with 
an HSPB1 (mutant or wild-type) gene and a β-globin gene (mutant or wild-type).  The 
mutant β-globin will contain the TNFα ARE, but the wild-type β-globin will not contain 
an ARE on its mRNA.  We will then perform the mRNA decay assay described in Aim 1 
on the β-globin mRNA.  
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To study the affect of HSPB1(R136W) on ARE-mediated mRNA decay in vivo, 
we must directly measure the rate of mRNA decay from tissue samples of HSPB1 and 
HSPB1(R136W) transgenic mice.  We can do this by isolating RNA directly from tissue 
samples of these mice or using laser-capture micro-dissection to isolate specific cell types 
from which the RNA can be extracted.  We will then convert the RNA to cDNA and 
quantitate the levels of mRNA via QPCR as described above.  We can use these 
techniques to measure the steady state of ARE-mediated mRNA decay in the mice, or we 
can stress the mice with an injection of LPS, and then measure the rate of ARE-mediated 
mRNA decay in response to cell stress.  We will be able to compare ARE-mediated 
mRNA decay in the PrP-HSPB1(R136W) mice to ARE-mediated mRNA decay in both 
PrP-HSPB1 mice and non-transgenic control mice.  In addition, it is necessary to develop 
a transgenic mouse expressing HSPB1(R136W) that develops a clinical neuropathy.  To 
do so, we are currently developing two BACs with HSPB1(R136W) or wild-type HSPB1 
that we will use to develop transgenic mice that ubiquitously express HSPB1(R136W) or 
wild-type HSPB1.  We will then directly measure the rate of ARE-mediated mRNA 
decay in these mice by the previously-stated techniques. 
We must also determine how HSPB3 and HSPB3(R7S) affect ARE-mediated 
mRNA decay.  To do so, we need to develop a successful transfection paradigm to 
express HSPB3 or HSPB3(R7S) either by a lenti-viral vector or another method for 
transfection.  We will then perform the mRNA decay assay as described above in those 
transfected macrophages.  It is also necessary to develop a transgenic mouse expressing 
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HSPB3 or HSPB3(R7S) to determine the affect of HSPB3 and HSPB3(R7S) on ARE-
mediated mRNA decay in vivo. 
We believe that mRNA processing may be part of the common mechanism of all 
MNDs.  Therefore, in addition to repeating the mRNA decay assay in models of dHMN 
and ALS, we must determine the effectiveness of ARE-mediated mRNA decay in models 
of other MNDs.   
Lastly, we would also like to determine whether the alpha-crystallin domain is 
particularly susceptible to mutation, what function the alpha-crystallin serves, and 
whether mutations in among the different sHSP domains affect different sHSP functions.   
 
Significance 
 There are no effective therapies for MNDs.   Mutations in sHSPs are linked to 
MNDs; specifically, mutations in HSPB1, HSPB3, and HSPB8 are known to cause 
dHMN [5-6, 9].  We believe that mutations in HSPB1, HSPB3, and HSPB8 all lead to the 
same functional consequences and act by a common mechanism to cause dHMN, and that 
this mechanism is common to MNDs in general.  Determining whether the mutations in 
HSPB1 and HSPB3 alter ARE-mediated mRNA decay in vitro and in vivo will help to 
uncover the mechanism of dHMN.  If the mutations in HSPB1 and HSPB3 have a 
harmful effect on ARE-mediated mRNA decay, then ARE-mediated mRNA decay may 
be part of the common mechanism of sHPS mutations leading to dHMN.    
In addition, we believe that a common pathway is affected in all MNDs.  We 
hypothesize that mRNA processing may be part of the common pathway.  Therefore, 
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studying ARE-mediated mRNA decay in a model ALS in addition to models of dHMN 
will help us determine if ARE-mediated mRNA decay is altered in models of both 
diseases, and therefore, if ARE-mediated mRNA decay is potentially part of the common 
mechanism of MNDs in general.  The knowledge of the mechanism of dHMN and MNDs 
will lead to new treatments for dHMN and MNDs that will extend and improve the 
quality of life of those living with these diseases. 
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